Zenas BioPharma to Take part in Upcoming Healthcare Investor Conferences

WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage international biopharmaceutical firm dedicated to being a frontrunner within the improvement and commercialization of transformative immunology-based therapies, right now introduced the Company’s participation on the following healthcare investor conferences:

• Guggenheim’s Inaugural Healthcare Innovation Conference on November 12, 2024, in Boston, MA
• Jefferies London Healthcare Conference on November 19, 2024 presentation at 4:00 p.m. to 4:25 p.m. GDT, in London
• Citi’s 2024 Global Healthcare Conference on December 3, 2024 presentation at 9:30 a.m. to 10:10 a.m. ET, in Miami, FL
• Evercore ISI HealthCONx Conference on December 4, 2024 presentation at 1:20 p.m. to 1:40 p.m. ET, in Coral Gables, FL

Live webcasts and archived replays of the Company’s displays on the Jefferies, Citi and Evercore conferences might be accessed below “Events and Presentations” within the Investors and Media part of the Zenas BioPharma website.

About Zenas BioPharma, Inc.

Zenas is a clinical-stage international biopharmaceutical firm dedicated to turning into a frontrunner within the improvement and commercialization of transformative immunology-based therapies for sufferers in want. Our core enterprise technique combines our skilled management crew with a disciplined product candidate acquisition method to establish, purchase and develop product candidates globally that we consider can present superior scientific advantages to sufferers residing with autoimmune ailments. Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind each CD19 and FcγRIIb, that are broadly current throughout B cell lineage, to inhibit the exercise of cells which are implicated in lots of autoimmune ailments with out depleting them. We consider that obexelimab’s mechanism of motion and persistent dosing routine might broadly and successfully deal with the pathogenic position of B cell lineage in persistent autoimmune illness. For extra details about Zenas BioPharma, please go to www.zenasbio.com and observe us on X at @ZenasBioPharma and LinkedIn.

The Zenas BioPharma phrase mark and logos are logos of Zenas BioPharma, Inc. or its affiliated corporations.

Investor Contact:
Matthew Osborne
Investor Relations and Corporate Communications
Matt.osborne@zenasbio.com

Media Contact:
Argot Partners
Zenas@argotpartners.com

GlobeNewswire Distribution ID 9268589